These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 9599200)
1. Antilymphocyte antibodies, renal transplantation, and meta-analysis. Levey AS; Schmid CH; Lau J Ann Intern Med; 1998 May; 128(10):863-5. PubMed ID: 9599200 [No Abstract] [Full Text] [Related]
2. The impact of antilymphocyte therapy on sensitized patients in renal transplantation. Santi S; Fop F; Segoloni G; Piccoli G Transplant Proc; 2001; 33(1-2):1090. PubMed ID: 11267204 [No Abstract] [Full Text] [Related]
3. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function. Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289 [No Abstract] [Full Text] [Related]
4. Single center experience with thymoglobulin in renal transplantation. Zaltzman JS; Paul LC Transplant Proc; 1997 Nov; 29(7A):27S-28S. PubMed ID: 9366924 [No Abstract] [Full Text] [Related]
5. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years. MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774 [No Abstract] [Full Text] [Related]
6. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Clark G; Walsh G; Deshpande P; Koffman G Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256 [TBL] [Abstract][Full Text] [Related]
7. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan. Takahashi K; Ochiai T; Uchida K; Yasumura T; Ishibashi M; Suzuki S; Otsubo O; Isono K; Takagi H; Oka T Transplant Proc; 1995 Feb; 27(1):1421-4. PubMed ID: 7878933 [No Abstract] [Full Text] [Related]
8. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation. Abouna GM; Kumar MS; Stephan R; Prior JE; Lyons P; Bulova SI; al-Abdullah IH Transplant Proc; 1993 Jun; 25(3):2241-2. PubMed ID: 8516886 [No Abstract] [Full Text] [Related]
9. Induction therapy with antithymocyte serum (NATS) increases graft survival and function in kidneys with initial poor function. Goldman MH; Regester RF; Freeman MB; Tyler B; Tyler JD Transplant Proc; 1991 Apr; 23(2):1753-4. PubMed ID: 2053143 [No Abstract] [Full Text] [Related]
10. Thymoglobulin and its use in renal transplantation: a review. Thiyagarajan UM; Ponnuswamy A; Bagul A Am J Nephrol; 2013; 37(6):586-601. PubMed ID: 23774740 [TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of 15-deoxyspergualin on late acute rejection occurring more than three months after renal transplantation. Amada N; Okazaki H; Sato T; Miura S; Ohashi Y Transplant Proc; 1998 Aug; 30(5):2246-7. PubMed ID: 9723458 [No Abstract] [Full Text] [Related]
12. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Tchervenkov J; Flemming C; Guttmann RD; des Gachons G Transplant Proc; 1997 Nov; 29(7A):13S-15S. PubMed ID: 9366919 [No Abstract] [Full Text] [Related]
13. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial. van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247 [No Abstract] [Full Text] [Related]
14. Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Hourmant M; Bedrossian J; Durand D; Kessler M; Le Branchu Y; Caudrelier P; Simi B; Soulillou JP Transplant Proc; 1995 Feb; 27(1):864. PubMed ID: 7879209 [No Abstract] [Full Text] [Related]
15. Induction therapy with rabbit antithymocyte sera reduces rejection episodes in immunologically low-risk living donor renal transplant recipients. Cardella CJ; Cattran D; Fenton SA; Albert S; Robinette M; Cole E Transplant Proc; 1997 Nov; 29(7A):29S-31S. PubMed ID: 9366925 [No Abstract] [Full Text] [Related]
17. The use of thymoglobuline induction in renal transplantation: a pharmacovigilance study. Hurault de Ligny B; Lebranchu Y Transplant Proc; 2000 Mar; 32(2):351-2. PubMed ID: 10715435 [No Abstract] [Full Text] [Related]
18. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K; Munn SR; Sterioff S Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
19. Long-term results of rabbit antithymocyte globulin and basiliximab induction. Brennan DC; Schnitzler MA N Engl J Med; 2008 Oct; 359(16):1736-8. PubMed ID: 18923181 [No Abstract] [Full Text] [Related]
20. Synergistic effect of immunosuppressive drug and intrathymic inoculation of donor cells in skin graft survival. Dono K; Wood ML; Ozato H; Monaco AP Transplant Proc; 1994 Oct; 26(5):3061. PubMed ID: 7940963 [No Abstract] [Full Text] [Related] [Next] [New Search]